Novartis Investor Presentation
New Novartis: Our strategy
Our focus
Our priorities
Conclusion
Abbreviations
Disclaimer
This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be
identified by words such as "potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek," "look forward,” “believe,” “committed," "investigational," "pipeline," "launch," or
similar terms, or by express or implied discussions regarding the potential completion of the proposed spin-off of Sandoz; regarding the future commercial performance of Novartis or of Sandoz;
regarding any potential strategic benefits, synergies or opportunities as a result of the proposed spin-off; regarding discussions of strategy, plans, expectations or intentions; regarding our ability
to deliver improved financial results, continuing development of to successfully launch new products and new indications for existing products, to deliver high value innovation, or improve access
to patients; or regarding potential benefits resulting from our organizational changes announced in April. You should not place undue reliance on these statements. Such forward-looking
statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no
guarantee that the proposed spin-off will be completed in the expected form or within the expected time frame or at all. Nor can there be any guarantee that Novartis or a separate Sandoz
business will be able to realize any of the potential strategic benefits, synergies or opportunities as a result of these actions. Neither can there be any guarantee that shareholders will achieve
any particular level of shareholder returns. Nor can there be any guarantee that the proposed spin-off of Sandoz will maximize value for shareholders, or that Novartis or any of its divisions, or a
separate Sandoz business, will be commercially successful in the future, or achieve any particular credit rating or financial results. Neither can there be any guarantee that we will be able to
improve our financial results, successfully launch new products and new indications for existing products, deliver high value innovation or improve access to patients. Nor can there be any
guarantee that our organizational changes announced in April will realize any or all of the expected benefits, or within any particular time frame. In particular, our expectations could be affected
by, among other things: an unexpected failure to complete, or unexpected delays in completing, the necessary actions for the proposed spin-off, or to obtain the necessary approvals to complete
these actions; the potential strategic benefits, synergies or opportunities expected from the proposed spin-off may not be realized or may take longer to realize than expected; regulatory actions
or delays or government regulation generally; the inherent uncertainty in predicting shareholder returns; the successful separation of Sandoz from Novartis and the timing of such separation;
potential adverse reactions to the proposed spin-off by customers, suppliers, strategic partners or key Sandoz personnel and potential difficulties in maintaining relationships with such persons; a
failure to improve our financial results, to successfully launch new products and new indications for existing products, to deliver high value innovation, or to improve access to patients; the
uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; global trends toward health care cost containment, including
government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property
protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases
such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and
other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this
date and does not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise.
Implementation of the proposed separation of Sandoz by way of a 100% spin-off is subject to certain conditions, including Novartis shareholder approval and applicable Novartis Euroforum and
local employee information and/or consultation.
Nuplazid® is a registered trademark of Acadia Pharmaceuticals Inc. Aduhelm® is a registered trademark of Biogen.
2
Novartis Investor Presentation | September 22, 2022
U
NOVARTIS | Reimagining MedicineView entire presentation